TY - JOUR
T1 - Adjuvant treatment of early colon cancer with micrometastases
T2 - Results of a national survey
AU - Short, Scott S.
AU - Stojadinovic, Alexander
AU - Nissan, Aviram
AU - Wainberg, Zev
AU - Dhall, Deepti
AU - Yao, Kathy
AU - Bilchik, Anton
PY - 2012/8/1
Y1 - 2012/8/1
N2 - Background and Objectives: Optimal adjuvant treatment for patients with Stage I/II colon cancer with micrometastases (MM) is unknown. Because there is no known adjuvant treatment-related benefit, we evaluated whether MM influenced treatment decisions. Method: Review of a national survey from members of the SSO and ASCO. Results: Of 602 survey responses, 305 (51%) stated that MM had significant prognostic value, 250 (42%) were unsure, and 47 (7%) did not believe that MM held prognostic value. Three hundred seventy-four (63%) would offer adjuvant therapy in the setting of MM, while 222 (37%) would not. Only 15% routinely performed IHC on lymph nodes. Medical oncologists were more likely to recommend adjuvant therapy compared to surgical oncologists (68% vs. 51%, P = 0.001). Conclusions: MM in colon cancer apparently influenced adjuvant treatment decisions absent known prognostic benefit. Prospective trials are needed to improve the selection of patients for systemic chemotherapy in early, node-negative colon cancer.
AB - Background and Objectives: Optimal adjuvant treatment for patients with Stage I/II colon cancer with micrometastases (MM) is unknown. Because there is no known adjuvant treatment-related benefit, we evaluated whether MM influenced treatment decisions. Method: Review of a national survey from members of the SSO and ASCO. Results: Of 602 survey responses, 305 (51%) stated that MM had significant prognostic value, 250 (42%) were unsure, and 47 (7%) did not believe that MM held prognostic value. Three hundred seventy-four (63%) would offer adjuvant therapy in the setting of MM, while 222 (37%) would not. Only 15% routinely performed IHC on lymph nodes. Medical oncologists were more likely to recommend adjuvant therapy compared to surgical oncologists (68% vs. 51%, P = 0.001). Conclusions: MM in colon cancer apparently influenced adjuvant treatment decisions absent known prognostic benefit. Prospective trials are needed to improve the selection of patients for systemic chemotherapy in early, node-negative colon cancer.
KW - adjuvant chemotherapy
KW - colon cancer
KW - lymph node metastases
KW - micrometastatic disease
UR - http://www.scopus.com/inward/record.url?scp=84863725493&partnerID=8YFLogxK
U2 - 10.1002/jso.23057
DO - 10.1002/jso.23057
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 22308106
AN - SCOPUS:84863725493
VL - 106
SP - 119
EP - 122
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
SN - 0022-4790
IS - 2
ER -
